Applied Imaging's CEO Carl W. Hull Talks to The Wall Street Transcript.Business Editors/Health & Medical Writers NEW YORK--(BUSINESS WIRE)--Oct. 2, 2001 The Wall Street Transcript A generic term for any kind of copy, particularly an official or certified representation of the record of what took place in a court during a trial or other legal proceeding. A transcript of record has published an in-depth interview with Carl W. Hull, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Applied Imaging (Nasdaq:AICX), in which he talks at length about the company's future. The entire 2,800-word interview is available free online at http://www.twst.com/ceos.htm Hull gives an overview of the company. "We are the leading provider of automated au·to·mate v. au·to·mat·ed, au·to·mat·ing, au·to·mates v.tr. 1. To convert to automatic operation: automate a factory. 2. microscopic microscopic /mi·cro·scop·ic/ (mi?kro-skop´ik) 1. of extremely small size; visible only by the aid of the microscope. 2. pertaining or relating to a microscope or to microscopy. imaging systems that are used in both cancer and genetics laboratories worldwide to provide clinical information on cancer or prenatal prenatal /pre·na·tal/ (-na´tal) preceding birth. pre·na·tal adj. Preceding birth. Also called antenatal. prenatal preceding birth. disorders. Specifically, we offer a full range of imaging solutions that allow for the direct examination of genes, chromosomes Chromosomes Spaghetti-like structures located within the nucleus (or central portion) of each cell. Chromosomes contain the genetic information necessary to direct the development and functioning of all cells and systems in the body. , and the cells that contain them. We have well over 2,000 systems installed at well over 1,000 clinical laboratories throughout the world, and we ship an additional 500 or more systems each year. Our revenues were $16.7 million last year, an increase of 18% over 1999." Hull explains, "I think that for the company's businesses, we really are fortunate to have a portfolio of two distinct products or families of products. The first, our genetic analysis systems, have been in the marketplace for over 15 years. These are products that are mature in the sense that they are very well developed, well accepted in the marketplace, and generating a significant volume of sales on an ongoing basis for the company. We are very pleased to have that broad product portfolio experience under our belt." Looking forward, Hull states, "We see the MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there (TM) system and some specific variants of the MDS(TM) as the central source of our top-line revenue growth over the next three to five years. Our recently announced strategic alliance with DAKO will substantially accelerate that program" This interview is part of a 179-page Biotechnology Issue available at http://www.twst.com/info/info423.htm or by calling 212/952-7433 The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion